These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 36819177)

  • 21. Prognostic value of the metabolic bulk volume in patients with diffuse large B-cell lymphoma on baseline
    Delaby G; Hubaut MA; Morschhauser F; Besson A; Huglo D; Herbaux C; Baillet C
    Leuk Lymphoma; 2020 Jul; 61(7):1584-1591. PubMed ID: 32100597
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Combination of baseline FDG PET/CT total metabolic tumour volume and gene expression profile have a robust predictive value in patients with diffuse large B-cell lymphoma.
    Toledano MN; Desbordes P; Banjar A; Gardin I; Vera P; Ruminy P; Jardin F; Tilly H; Becker S
    Eur J Nucl Med Mol Imaging; 2018 May; 45(5):680-688. PubMed ID: 29344718
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Baseline Total Metabolic Tumor Volume and Total Lesion Glycolysis Measured on 18F-FDG PET-CT Predict Outcomes in T-Cell Lymphoblastic Lymphoma.
    Feng X; Wen X; Li L; Sun Z; Li X; Zhang L; Wu J; Fu X; Wang X; Yu H; Ma X; Zhang X; Xie X; Han X; Zhang M
    Cancer Res Treat; 2021 Jul; 53(3):837-846. PubMed ID: 33285054
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Prognostic value of visual IMPeTUs criteria and metabolic tumor burden at baseline [
    Marchiori S; Cousin F; Papadopoulos I; Bernard C; Thys M; De Prijck B; Pirotte M; Donneau AF; Hustinx R; Caers J; Withofs N
    EJNMMI Res; 2024 May; 14(1):51. PubMed ID: 38806885
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Tumor fragmentation estimated by volume surface ratio of tumors measured on 18F-FDG PET/CT is an independent prognostic factor of diffuse large B-cell lymphoma.
    Decazes P; Becker S; Toledano MN; Vera P; Desbordes P; Jardin F; Tilly H; Gardin I
    Eur J Nucl Med Mol Imaging; 2018 Sep; 45(10):1672-1679. PubMed ID: 29705879
    [TBL] [Abstract][Full Text] [Related]  

  • 26. 2-[
    Albano D; Calabrò A; Talin A; Dondi F; Pagani C; Tucci A; Treglia G; Bertagna F
    Ann Hematol; 2024 Jul; 103(7):2419-2427. PubMed ID: 38374254
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A different perspective on PET/CT before treatment in patients with Hodgkin lymphoma: importance of volumetric and dissemination parameters.
    Aksu A; Küçüker KA; Solmaz Ş; Turgut B
    Ann Hematol; 2024 Mar; 103(3):813-822. PubMed ID: 37964021
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Tumor Location Relative to the Spleen Is a Prognostic Factor in Lymphoma Patients: A Demonstration from the REMARC Trial.
    Girum KB; Cottereau AS; Vercellino L; Rebaud L; Clerc J; Casasnovas O; Morschhauser F; Thieblemont C; Buvat I
    J Nucl Med; 2024 Feb; 65(2):313-319. PubMed ID: 38071535
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Predictive value of baseline
    Zhu L; Meng Y; Guo L; Zhao H; Shi Y; Li S; Wang A; Zhang X; Shi J; Zhu J; Xu K
    Oncol Lett; 2021 Feb; 21(2):132. PubMed ID: 33552253
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Prognostic value of baseline metabolic tumor volume and total lesion glycolysis in patients with lymphoma: A meta-analysis.
    Guo B; Tan X; Ke Q; Cen H
    PLoS One; 2019; 14(1):e0210224. PubMed ID: 30625203
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Prognostic value of baseline
    Zhou Y; Hong Z; Zhou M; Sang S; Zhang B; Li J; Li Q; Wu Y; Deng S
    J Med Imaging Radiat Oncol; 2020 Feb; 64(1):87-95. PubMed ID: 31880103
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Total metabolic tumor volume on
    Tricarico P; Chardin D; Martin N; Contu S; Hugonnet F; Otto J; Humbert O
    J Immunother Cancer; 2024 Apr; 12(4):. PubMed ID: 38649279
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Volumetric parameters from [
    Langen Stokmo H; Aly M; Bowitz Lothe IM; Borja AJ; Mehdizadeh Seraj S; Ghorpade R; Miao X; Hjortland GO; Malinen E; Sorbye H; Werner TJ; Alavi A; Revheim ME
    J Neuroendocrinol; 2022 Jul; 34(7):e13170. PubMed ID: 35729738
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Metabolic parameters of pretreatment 2-[
    Li C; Dong Y; Pan Y; Han Y; Zhang J; Luan X; Liu J; Xu X; Guan Z; Wang G; Xu B
    Quant Imaging Med Surg; 2024 Jan; 14(1):604-617. PubMed ID: 38223061
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Prognostic value of baseline metabolic tumor volume in early-stage Hodgkin lymphoma in the standard arm of the H10 trial.
    Cottereau AS; Versari A; Loft A; Casasnovas O; Bellei M; Ricci R; Bardet S; Castagnoli A; Brice P; Raemaekers J; Deau B; Fortpied C; Raveloarivahy T; Van Zele E; Chartier L; Vander Borght T; Federico M; Hutchings M; Ricardi U; Andre M; Meignan M
    Blood; 2018 Mar; 131(13):1456-1463. PubMed ID: 29437590
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Baseline Metabolic Tumor Volume Predicts Outcome in High-Tumor-Burden Follicular Lymphoma: A Pooled Analysis of Three Multicenter Studies.
    Meignan M; Cottereau AS; Versari A; Chartier L; Dupuis J; Boussetta S; Grassi I; Casasnovas RO; Haioun C; Tilly H; Tarantino V; Dubreuil J; Federico M; Salles G; Luminari S; Trotman J
    J Clin Oncol; 2016 Oct; 34(30):3618-3626. PubMed ID: 27551111
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pre-treatment [18F]FDG PET/CT biomarkers for the prediction of antibody-drug conjugates efficacy in metastatic breast cancer.
    Seban RD; Champion L; De Moura A; Lerebours F; Loirat D; Pierga JY; Djerroudi L; Genevee T; Huchet V; Jehanno N; Bidard FC; Buvat I
    Eur J Nucl Med Mol Imaging; 2024 Oct; ():. PubMed ID: 39373900
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Molecular Profile and FDG-PET/CT Total Metabolic Tumor Volume Improve Risk Classification at Diagnosis for Patients with Diffuse Large B-Cell Lymphoma.
    Cottereau AS; Lanic H; Mareschal S; Meignan M; Vera P; Tilly H; Jardin F; Becker S
    Clin Cancer Res; 2016 Aug; 22(15):3801-9. PubMed ID: 26936916
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Predictive Value of PET Response Combined with Baseline Metabolic Tumor Volume in Peripheral T-Cell Lymphoma Patients.
    Cottereau AS; El-Galaly TC; Becker S; Broussais F; Petersen LJ; Bonnet C; Prior JO; Tilly H; Hutchings M; Casasnovas O; Meignan M
    J Nucl Med; 2018 Apr; 59(4):589-595. PubMed ID: 28864629
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The prognostic relationship of 18F-FDG PET/CT metabolic and volumetric parameters in metastatic ALK + NSCLC.
    Agüloğlu N; Aksu A; Unat DS; Akyol M
    Nucl Med Commun; 2022 Dec; 43(12):1217-1224. PubMed ID: 36345766
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.